The selected channel has been deleted from your list of favorites.

Our News on Newswise

Newswise: 66202ab868047_PRAAASAwardPR2024.jpg

Four MD Anderson researchers elected AAAS Fellows

In recognition of their significant achievements in the realm of cancer care and research, four researchers at The University of Texas MD Anderson Cancer Center have been elected fellows of the American Association for the Advancement of Science...
18-Apr-2024 9:05 AM EDT Add to Favorites

MD Anderson and CureVac enter strategic collaboration to develop novel cancer vaccines

MD Anderson and CureVac today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
16-Apr-2024 7:00 AM EDT Add to Favorites

MD Anderson Research Highlights for April 12, 2024

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s...
12-Apr-2024 12:00 PM EDT Add to Favorites

Newswise: 660ef0dcf3df0_paolostrati.jpg.resize.405.575.high.jpg

AACR: Trio of studies highlights promising early results with new cancer therapies and targets

Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2024 show promising initial data for patients with lymphoma,...
4-Apr-2024 2:05 PM EDT Add to Favorites

Newswise: 660ef982b4663_147793KopetzS.jpg

AACR: Combination treatment is well-tolerated, shows antitumor effects in KRAS G12C-mutated metastatic colorectal cancer

Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC), according to pooled results from the Phase I/II...
4-Apr-2024 3:30 PM EDT Add to Favorites

Newswise: 660eea98481f9_timothyyap.jpg.resize.405.575.high.jpg

AACR: PARP1-selective inhibitor demonstrates early efficacy in breast cancers with DNA repair defects

The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results from the Phase I/II...
4-Apr-2024 1:05 PM EDT Add to Favorites

Newswise: 660ef72d4439d_168780SrourS.jpg

AACR: Novel immunotherapies show promise for patients with kidney cancer and for solid organ transplant recipients with skin cancer

Researchers from The University of Texas MD Anderson Cancer Center presented encouraging findings today from two clinical trials in a plenary session highlighting advances in novel immunotherapy approaches at the American Association for Cancer...
4-Apr-2024 3:00 PM EDT Add to Favorites

MD Anderson Research Highlights: AACR 2024 Special Edition

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s...
4-Apr-2024 3:00 PM EDT Add to Favorites


See All News

Our Experts on Newswise

Newswise: BenjaminSmith.jpg

Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer

In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
27-Sep-2016 3:05 PM EDT

Newswise: Liang_H_Bronto.jpg

Can Gender Play a Role in Determining Cancer Treatment Choices?

It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
9-May-2016 12:00 PM EDT

Newswise: ZhiminLu.jpg

MD Anderson Study Reveals New Insight Into Tumor Progression

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.
17-Aug-2015 11:00 AM EDT

Newswise: Lee_M.jpg

Poor Survival Among Colorectal Cancer Patients Tied to Biomarker CSN6

A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.
10-Aug-2015 12:00 PM EDT

Newswise: 204929_Chhatwal_Jjpg.jpg

MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by...
16-Mar-2015 6:00 PM EDT

MD Anderson Joins CATCH Global Foundation to Boost Child Health, Prevent Cancer in Later Years

Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings...
18-Feb-2015 10:00 AM EST

See All Experts

Our YouTube Videos

About

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Experts

Contacts

McKenna Bauer
Communications Specialist - Public Relations

MMBauer@mdanderson.org

Aubrey Bloom
Program Manager, Public Relations

ARBloom@mdanderson.org

830-377-8566

Clayton Boldt
Program Director, Public Relations

CRBoldt@MDAnderson.org

713-792-9518

Andrea Bolt
Sr. Communications Specialist

ARBolt@MDAnderson.org

Lany Kimmons
Program Manager, Public Relations

rlkimmons@mdanderson.org

713-563-5801

Jamie Mauracher
Program Manager

JRMauracher@MDAnderson.org

Julie Nagy
Program Manager, Public Relations

jenagy@mdanderson.org

713-563-3437

Elise Raymund
Sr. Communication Specialist

ERRaymund@mdanderson.org

346-725-0943

Allison Schaffer
Program Manager, Public Relations

ASchaffer@mdanderson.org

713-745-1357

Jade Waddy
Program Manager, Public Relations

JAWaddy@mdanderson.org

346-725-2126

Twitter

close
1.27338